Immunic, Inc. InvestorRoom

News Releases

January 11, 2018

FDA approves IND for Immunic Therapeutics’ IMU-838 to proceed with Phase 2 study in ulcerative colitis

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838
December 12, 2017

Immunic Therapeutics Successfully Completes two Phase 1 Studies for IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed
September 5, 2017

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing
February 1, 2017

Immunic Adds EUR 4 Million in Funding to Further Boost Development

Series A financing round extended to EUR 21.7 Million

Show per page